Case Report
A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis
Table 1
Nerve conduction study.
| Nerve (right side) | Day of examination | Wrist or ankle latency, ms (amplitude) | Elbow or knee latency, ms (amplitude) | Velocity (m/s) |
| Median | Right | Motor | 10 | 3.30 (16.7 mV) | 6.93 (16.4 mV) | 57.9 | 38 | 3.39 (11.6 mV) | 8.16 (2.7 mV) | 45.0 | Sensory | 10 | 2.64 (2.3 µV) | — | 51.1 | 38 | 2.98 (3.7 µV) | — | 50.3 | Left | Motor | 10 | 3.51 (3.9 mV) | 7.32 (3.5 mV) | 52.5 | Sensory | 10 | 2.46 (4.3 µV) | — | 64.2 | Ulnar | Right | Motor | 10 | 2.67 (7.7 mV) | 7.32 (4.0 mV) | 44.1 | 38 | 2.76 (11.2 mV) | 7.32 (10.9 mV) | 54.2 | Sensory | 10 | 2.30 (2.3 µV) | — | 60.9 | 38 | 2.42 (2.1 µV) | — | 53.7 | Left | Motor | 10 | 2.88 (0.10 mV) | 8.07 (0.05 mV) | 33.7 | Sensory | 10 | n.e. | — | — | Tibial | Right | Motor | 10 | 4.30 (0.07 mV) | n.e. | — | Sural | Right | Sensory | 10 | n.e. | — | — |
|
|
Day of examination, number of days since nivolumab administration; n.e., not evoked. Abnormal data are italicized.
|